In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alembic Pharmaceuticals Limited

http://www.alembic-india.com/

Latest From Alembic Pharmaceuticals Limited

India FY22 Earnings: Everyone’s Talking Of Big Spikes In Input, Logistics Costs

The sharp escalation in prices of raw materials, solvents, excipients and logistics in a volatile operating environment charged by geopolitical tensions and supply chain challenges was one of the key talking points at the fiscal fourth quarter earnings discussions of leading Indian firms. With little hope for respite any time soon, companies are devising strategies to cope.

Commercial India

Alembic Remains Upbeat Despite Rhizen Setback

Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has 15-plus launches lined up.

Sales & Earnings India

Setback For Alembic-backed Rhizen After Concerns Over PI3K Inhibitors

Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has15-plus launches lined up.

Commercial India

Lupin’s Foncoo Partnership Beginning Of China Challenge To AZ, Cipla?

Lupin’s partnership with Shenzhen Foncoo marks the Indian firm's much-awaited entry into China. Will this and more planned alliances make Lupin a worthy respiratory challenger to AstraZeneca, compatriot Cipla and others in a country where chronic respiratory diseases are the second leading cause of death?

China Deals
See All

Company Information

  • Industry
  • Services
    • Hospitals, Nursing Homes, Institutions
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Orit Laboratories Alembic Global Holding SA Aleor Dermaceuticals Limited Alembic Pharmaceuticals Australia Pty Limited Alembic Pharmaceuticals Europe Limited Alembic Pharmaceuticals Inc Alembic Pharmacueticals Canada Limited Alnova Pharmaceuticals SA Genius LLC
UsernamePublicRestriction

Register